LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES —   A MANDATE FOR CARDIOLOGIST AND INTERNIST

LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES —   A MANDATE FOR CARDIOLOGIST AND INTERNIST

The data from a range of large trials (LEADER, EMPA-REG, CANVAS) show evidently the practical use of the modern glucose lowering drugs usage for successful management of cardiovascular risk in type 2 diabetes (DM2) patients. The article is focused on analysis and review of possible mechanisms and be...

Full description

Bibliographic Details
Main Author: S. V. Nedogoda
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC  2018-05-01
Series:Российский кардиологический журнал
Subjects:
diabetes
cardiovascular risk
liraglutide
glucagon-like peptide 1
adipokines
Online Access:https://russjcardiol.elpub.ru/jour/article/view/2717
id doaj-1ff7874428e34be7a1b9f1eda46ddb76
record_format Article
spelling doaj-1ff7874428e34be7a1b9f1eda46ddb762021-07-28T14:02:32Zrus«FIRMA «SILICEA» LLC Российский кардиологический журнал1560-40712618-76202018-05-0104899210.15829/1560-4071-2018-4-89-922369LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES —   A MANDATE FOR CARDIOLOGIST AND INTERNISTS. V. Nedogoda0Volgograd State Medical University of the Ministry of Health.The data from a range of large trials (LEADER, EMPA-REG, CANVAS) show evidently the practical use of the modern glucose lowering drugs usage for successful management of cardiovascular risk in type 2 diabetes (DM2) patients. The article is focused on analysis and review of possible mechanisms and benefits of cardiovascular risk reduction in DM2 with prescription of the antagonist of glucagonlike peptide 1 — liraglutide (Victoza®).https://russjcardiol.elpub.ru/jour/article/view/2717diabetescardiovascular riskliraglutideglucagon-like peptide 1adipokines
collection DOAJ
language Russian
format Article
sources DOAJ
author S. V. Nedogoda
spellingShingle S. V. Nedogoda
LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES —   A MANDATE FOR CARDIOLOGIST AND INTERNIST
Российский кардиологический журнал
diabetes
cardiovascular risk
liraglutide
glucagon-like peptide 1
adipokines
author_facet S. V. Nedogoda
author_sort S. V. Nedogoda
title LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES —   A MANDATE FOR CARDIOLOGIST AND INTERNIST
title_short LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES —   A MANDATE FOR CARDIOLOGIST AND INTERNIST
title_full LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES —   A MANDATE FOR CARDIOLOGIST AND INTERNIST
title_fullStr LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES —   A MANDATE FOR CARDIOLOGIST AND INTERNIST
title_full_unstemmed LIRAGLUTIDE PLEIOTROPIC EFFECT IN CARDIOVASCULAR RISK REDUCTION IN TYPE 2 DIAbETES —   A MANDATE FOR CARDIOLOGIST AND INTERNIST
title_sort liraglutide pleiotropic effect in cardiovascular risk reduction in type 2 diabetes —   a mandate for cardiologist and internist
publisher «FIRMA «SILICEA» LLC 
series Российский кардиологический журнал
issn 1560-4071
2618-7620
publishDate 2018-05-01
description The data from a range of large trials (LEADER, EMPA-REG, CANVAS) show evidently the practical use of the modern glucose lowering drugs usage for successful management of cardiovascular risk in type 2 diabetes (DM2) patients. The article is focused on analysis and review of possible mechanisms and benefits of cardiovascular risk reduction in DM2 with prescription of the antagonist of glucagonlike peptide 1 — liraglutide (Victoza®).
topic diabetes
cardiovascular risk
liraglutide
glucagon-like peptide 1
adipokines
url https://russjcardiol.elpub.ru/jour/article/view/2717
work_keys_str_mv AT svnedogoda liraglutidepleiotropiceffectincardiovascularriskreductionintype2diabetesamandateforcardiologistandinternist
_version_ 1721269091774234624

Similar Items